Possis Delays New Vascular Graft Launch; May Sell Off Entire Division
This article was originally published in The Gray Sheet
Executive SummaryPossis is shelving plans to market its newly approved Perma-Seal silicon elastomer access graft pending a strategic review of the firm's entire vascular graft division by Salomon Smith Barney due Nov. 1.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
HBW Market News: FTC Ends Another Supplement Scam, Australia Win For ChromaDex, GOED Report, Herbalife
Herbalife opens 9,200 square-foot training facility in China; GOED's latest annual market report, covering 2017-2018, is available; ChromaDex has two-tear exclusivity for nicotinamide riboside chloride in Australia; and A.S. Research arthritis claims for Synovia end in FTC settlement.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.